CD8A and neoplasm: The combination therapy converts ‘cold’ tumors into immunologically ‘hot’ ones by increasing intratumoral CD8+ T cell infiltration, while LRT reduces tumor mass and intratumoral hypoxia, making tumor cells more susceptible to immune-mediated killing.